Abstract CT205: Neoadjuvant (Z)-endoxifen in premenopausal ER+, HER2- breast cancer: Evaluation of the first pharmacokinetic cohort of the EVANGELINE trialMatthew P. Goetz, Steven C. Quay, Mara A. Piltin et al.|Cancer Research|2024Cited by 1
Abstract CT237: A randomized phase 2 non-inferiority trial of (Z)-endoxifen + goserelin and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE)Matthew P. Goetz, Steven C. Quay, Vera J. Suman et al.|Cancer Research|2025Cited by 0
Abstract P2-03-07: Neoadjuvant (Z)-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor 2 (HER2)- Breast Cancer (BC): Evaluation of Quality of Life (QOL) measures in the EVANGELINE StudySarah Premji, Matthew P. Goetz, Vera J. Suman et al.|Clinical Cancer Research|2025Cited by 0
Abstract P2-12-18: A Randomized Phase 2 Non-inferiority Trial of (Z)-endoxifen and Exemestane + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+/HER2-Breast Cancer (EVANGELINE)Matthew Bidwell Goetz, Steven C. Quay, Vera J. Suman et al.|Clinical Cancer Research|2025Cited by 0
Abstract P1-11-04: Neoadjuvant Z-endoxifen for Premenopausal Estrogen Receptor (ER)+, Human Epidermal Growth Factor Receptor (HER2)- Breast Cancer (BC): Evaluation of the Pharmacokinetic (PK) Run-in for the EVANGELINE StudyMatthew Bidwell Goetz, Steven C. Quay, Vera J. Suman et al.|Clinical Cancer Research|2025Cited by 0